Patient Resources

Genitope Corporation is committed to helping patients who are diagnosed with B-cell malignancies. First and foremost, our company is focused on developing a personalized active immunotherapy product for patients with non-Hodgkin’s lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL). MyVax® Personalized Immunotherapy is being tested in a pivotal Phase 3 trial in patients with previously untreated stage III-IV follicular NHL, in a Phase 1/2 trial evaluating previously untreated patients with CLL Rai stage O, I, and II, and in a Phase 2 trial in patients with previously untreated stage III-IV follicular NHL who require treatment and are able to receive rituximab in combination with chemotherapy. Other Phase 2 trials in patients with B-cell NHL are either ongoing or have been completed. Through our website, Genitope Corporation strives to provide patients with the information necessary to make an educated and informed decision regarding their treatment options.

Below are several areas that patients may find especially useful (click on the underlined words to link to the specific sections):

  • The Clinical Trials section provides information about Genitope's closed clinical studies. Here, you will find:
    • A contact form to use if you have any questions or are interested in receiving further information about our clinical trials.
  • The Product Overview section describes our lead therapeutic product, MyVax® Personalized Immunotherapy, and how we make it.
  • This Patient Resources area provides educational resources for lymphoma patients and their caregivers. Here, you will find:
    • Patient Brochure - a resource containing background information on personalized active immunotherapy and using the immune system to fight cancer
    • General FAQs - a list of frequently asked questions and answers about Genitope's lead therapeutic product, MyVax® Personalized Immunotherapy
    • R-Chemo Trial FAQs – a list of frequently asked questions about Genitope’s Phase 2 trial in patients with previously untreated stage III-IV follicular NHL who require treatment and are able to receive rituximab in combination with chemotherapy (R-Chemo).
    • CLL Trial FAQs – a list of frequently asked questions about Genitope’s Phase 1/2 trial in patients with untreated, Chronic Lymphocytic Leukemia (CLL), Rai stage 0, I, and II
    • Other Resources - a list of organizations providing information and services relevant to the lymphoma community
    • Calendar of Events - a list of nationwide educational programs and conferences for lymphoma patients in which Genitope has participated or plans to participate